Pharmacological chaperone for α-crystallin partially restores transparency in cataract models
Leah N Makley,Kathryn A McMenimen,Brian T DeVree,Joshua W Goldman,Brittney N McGlasson,Ponni Rajagopal,Bryan M Dunyak,Thomas J McQuade,Andrea D Thompson,Roger Sunahara,Rachel E Klevit,Usha P Andley,Jason E Gestwicki,Leah N. Makley,Kathryn A. McMenimen,Brian T. DeVree,Joshua W. Goldman,Brittney N. McGlasson,Bryan M. Dunyak,Thomas J. McQuade,Andrea D. Thompson,Rachel E. Klevit,Usha P. Andley,Jason E. Gestwicki
DOI: https://doi.org/10.1126/science.aac9145
IF: 56.9
2015-11-06
Science
Abstract:A visionary approach to transparency Cataracts are the most common cause of vision loss, especially in our ever-increasing elderly population. Cataracts arise when crystallin, a major protein component of the eye lens, begins to aggregate, which causes the lens to become cloudy. Makley et al. explored whether small molecules that reverse this aggregation might have therapeutic potential for treating cataracts, which normally require surgery (see the Perspective by Quinlan). They used a screening method that monitors the effect of ligands on temperature-dependent protein unfolding and identified several compounds that bind and stabilize the soluble form of crystallin. In proof-of-concept studies, one of these compounds improved lens transparency in mice. Science , this issue p. 674 ; see also p. 636
multidisciplinary sciences